Minerva Neurosciences, Inc (NERV) Holdings Raised by DAFNA Capital Management LLC
DAFNA Capital Management LLC raised its holdings in shares of Minerva Neurosciences, Inc (NASDAQ:NERV) by 172.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 276,317 shares of the biopharmaceutical company’s stock after purchasing an additional 175,000 shares during the quarter. Minerva Neurosciences accounts for 1.7% of DAFNA Capital Management LLC’s portfolio, making the stock its 16th largest position. DAFNA Capital Management LLC owned 0.65% of Minerva Neurosciences worth $2,445,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. State of Wisconsin Investment Board acquired a new stake in Minerva Neurosciences during the 2nd quarter valued at approximately $159,000. Vanguard Group Inc. grew its stake in Minerva Neurosciences by 13.4% during the 1st quarter. Vanguard Group Inc. now owns 939,297 shares of the biopharmaceutical company’s stock valued at $7,608,000 after purchasing an additional 110,876 shares in the last quarter. Laurion Capital Management LP acquired a new stake in Minerva Neurosciences during the 2nd quarter valued at approximately $326,000. ClariVest Asset Management LLC grew its stake in Minerva Neurosciences by 1.0% during the 1st quarter. ClariVest Asset Management LLC now owns 29,200 shares of the biopharmaceutical company’s stock valued at $236,000 after purchasing an additional 300 shares in the last quarter. Finally, Nexthera Capital LP grew its stake in Minerva Neurosciences by 53.6% during the 1st quarter. Nexthera Capital LP now owns 757,200 shares of the biopharmaceutical company’s stock valued at $6,133,000 after purchasing an additional 264,242 shares in the last quarter. Hedge funds and other institutional investors own 69.29% of the company’s stock.
A number of equities research analysts have weighed in on the company. Zacks Investment Research lowered Minerva Neurosciences from a “buy” rating to a “hold” rating in a research note on Thursday. Citigroup Inc. started coverage on Minerva Neurosciences in a research report on Friday, September 1st. They issued a “buy” rating and a $11.00 target price for the company. Finally, BidaskClub lowered Minerva Neurosciences from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Minerva Neurosciences presently has a consensus rating of “Hold” and an average target price of $13.94.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/05/minerva-neurosciences-inc-nerv-holdings-raised-by-dafna-capital-management-llc.html.
Shares of Minerva Neurosciences, Inc (NASDAQ NERV) traded up 1.30% on Thursday, hitting $7.80. The stock had a trading volume of 60,783 shares. Minerva Neurosciences, Inc has a 1-year low of $5.55 and a 1-year high of $14.59. The stock’s market cap is $331.57 million. The firm’s 50-day moving average is $6.76 and its 200 day moving average is $7.67.
Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.07. During the same period in the prior year, the business earned ($0.18) EPS. Equities analysts forecast that Minerva Neurosciences, Inc will post ($0.90) EPS for the current year.
About Minerva Neurosciences
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Stock Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related stocks with our FREE daily email newsletter.